HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

DHR

Danaher Corporation (S&P 500)

Healthcare — Diagnostics & Research

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Strong Buy 1.5 / 5 23 analysts
$199.05
+$2.55 (+1.30%)
Target: $227.61 (14.3%)
Sign in to add DHR to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$139.93B
P/E Ratio (TTM)35.54
Forward P/E21.50
EPS (TTM)$5.60
Dividend Yield0.81%
Profit Margin15.95%
Revenue Growth5.50%
ROE7.61%
Debt/Equity52.97
Recommendation Strong Buy 1.5
Analyst Target$227.61
Analysts23
Indexes S&P 500

Technical Indicators

RSI (14)56.4
Beta0.82
SMA 20$195.17
SMA 40$189.26
52-Week High$242.80
52-Week Low$160.93
50-Day Avg$185.09
200-Day Avg$203.86
Avg Volume$5.12M
Volume$9.36M

Performance Analysis

BULLISH

DHR shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 47% of its 52-week range.
+ RSI at 56.4 shows positive momentum.
~ Modest revenue growth of 5.5% year-over-year.
+ Wall Street consensus is "Strong Buy" from 23 analysts.
+ Average analyst target of $227.61 implies 14.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:00 UTC

Back to Screener Export Report